Skip to main content

Day: June 1, 2023

Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

Features Preclinical data of PAS-004 in Plexiform Neurofibroma PALO ALTO, Calif. and MIAMI, June 01, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, today announced that pre-clinical results for its lead drug candidate, PAS-004, have been accepted for a poster presentation at the 2023 Neurofibromatosis (NF) Conference taking place June 24-27, 2023, in Scottsdale, Arizona. “We are extremely pleased to be presenting preclinical data from PAS-004 conducted in collaboration with Dr. Wade Clapp at Indiana University, School of Medicine,” commented Dr. Graeme Currie, Pasithea’s Chief Development Officer. “The presentation will provide insight...

Continue reading

Getty Images and iStock Empower Emerging Creatives Through New Accelerator Program

Open call for global creators through July 10th to participate in a one-year intensive program offering industry-led support to amplify underrepresented communities in the content development space A Media Snippet accompanying this announcement is available by clicking on the image or link below:NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) — Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, and iStock, a leading e‑commerce platform providing premium visual content to SMBs, SMEs and creatives everywhere, have today announced the launch of their Creative Accelerator Program, a new initiative aimed at recruiting and onboarding early to mid-career creators from underrepresented backgrounds and demographics to shape the next generation of talent. Successful applicants will receive support from leading...

Continue reading

Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma

AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, announced today that the U.S. Food and Drug Administration (“FDA”), after reviewing safety data on the program, has removed the partial clinical hold on patient enrollment for its MT-0169 trial, allowing Molecular Templates to proceed with its plan to evaluate the efficacy of MT-0169, one of its ETBs, which specifically targets CD38, a validated target in Multiple Myeloma. The FDA placed the Phase I study for MT-0169 on a partial clinical hold in April 2023, based...

Continue reading

Capital Square Partners and Basil Technology Partners announce completion of merger to create one of the largest cross-border, technology services fund manager in Asia

SINGAPORE, June 01, 2023 (GLOBE NEWSWIRE) — Capital Square Partners (“CSP”) and Basil Technology Partners (“BTP”) today announced that they have completed the merger of the two teams and would henceforth operate as CSP. With this merger, CSP aims to consolidate its position as one of the largest cross-border, technology services dedicated private equity fund manager in Asia and will continue to augment its combined execution capability. “Following the successful closing of CSP Fund II, c.US$ 700 million fund, announced in January through a partnership between CSP and BTP, the teams had been working very closely over the past few months. To ensure a seamless, streamlined and efficient execution of our investment thesis, both teams felt it would be better to merge and operate as one team. We will continue to focus on our core competence,...

Continue reading

Cibus Announces Closing of Merger with Calyxt to Create Industry Leading Precision Gene Editing and Trait Development Company

Cibus Class A Common Stock to commence trading on Nasdaq Capital Market on June 1, 2023 under ticker symbol “CBUS” Merger follows closing of $118.5 million private financing by Cibus Global SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) — Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced the closing of its previously announced merger with Calyxt, Inc. (“Calyxt”). In connection with, and immediately preceding, the closing of the merger, Calyxt effected the previously announced reverse stock split of Calyxt common stock at a ratio of 1-for-5. Calyxt filed an amendment to its amended and restated certificate of incorporation to effectuate the reverse stock split as of 4:01 p.m. Eastern Time on May 31, 2023. The combined company...

Continue reading

Lifeist Wellness to Acquire Fast-Growing ‘Zest’ Brand

Lifeist to acquire ‘Zest’ brand to drive growth through expanded marketing and sales as a complimentary product line to its in-house concentrate brand, Roilty TORONTO, June 01, 2023 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, is pleased to announce it has entered into a definitive share purchase agreement (the “Share Purchase Agreement”), pursuant to which the Company will acquire 100% of 1000501971 Ontario Inc. (“Zest”) for $3,411,707.90 (the “Acquisition”). The Acquisition is an all-stock transaction, marking another significant milestone for Lifeist’s expansion strategy. About the ‘Zest’ Brand The ‘Zest’ brand launched...

Continue reading

Asante Gold Announces FY 2023 Results

VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) — Asante Gold Corporation (“Asante” or the “Company” CSE:ASE | GSE:ASG | FRANKFURT:1A9 | U.S.OTC:ASGOF) announces the filing of its audited financials, management’s discussion and analysis and annual information form for the year ended January 31, 2023 (the “Annual Filings”). All financial information provided in this news release is audited and dollar figures are Canadian dollars unless otherwise stated. FY 2023 HIGHLIGHTSNo Lost Time Injuries recorded. Gold production and sales of 120,713 ounces. Revenue of $274.7 million. Net comprehensive loss of $169.5 million. Completed US$60 million in deferred payments for Bibiani acquisition. Completed US$52 million in payments pursuant to the Company’s gold forward sale agreement. Closed acquisition of an indirect 90% interest...

Continue reading

Gaming and Leisure Properties, Inc. Declares Second Quarter 2023 Cash Dividend of $0.72 Per Share

WYOMISSING, Pa., June 01, 2023 (GLOBE NEWSWIRE) — Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) (the “Company”) announced today that the Company’s Board of Directors has declared the second quarter 2023 cash dividend of $0.72 per share of its common stock. The dividend is payable on June 30, 2023 to shareholders of record on June 16, 2023. The second quarter 2022 cash dividend was $0.705 per share of the Company’s common stock. While the Company intends to pay regular quarterly cash dividends for the foreseeable future, all subsequent dividends will be reviewed quarterly and declared by the Board of Directors at its discretion. About Gaming and Leisure PropertiesGLPI is engaged in the business of acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements, pursuant...

Continue reading

Plymouth Industrial REIT Declares Second Quarter 2023 Preferred Stock Dividend

BOSTON, June 01, 2023 (GLOBE NEWSWIRE) — Plymouth Industrial REIT, Inc. (NYSE: PLYM) today announced that the Company’s board of directors has declared a regular quarterly cash dividend of $0.46875 per share, or an annualized dividend of $1.875 per share, for the Company’s 7.50% Series A Cumulative Redeemable Preferred Stock (PLYM-PrA) for the second quarter of 2023. The dividend is payable on June 30, 2023, to stockholders of record on June 15, 2023. About Plymouth Plymouth Industrial REIT, Inc. (NYSE: PLYM) is a full service, vertically integrated real estate investment company focused on the acquisition, ownership and management of single and multi-tenant industrial properties. Our mission is to provide tenants with cost effective space that is functional, flexible and safe.Contact:    Tripp Sullivan    SCR Partners    (615)...

Continue reading

Lyra Therapeutics Announces Closing of $50.0 Million Private Placement

WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced the closing of its previously announced private placement of common stock, pre-funded warrants to purchase common stock and purchase warrants to purchase common stock, resulting in gross proceeds of approximately $50.0 million. The private placement includes participation from new and existing investors, including Perceptive Advisors, Venrock Healthcare Capital Partners, Armistice Capital, Surveyor Capital (a Citadel company), North Bridge Venture Partners, Nantahala Capital, Samsara BioCapital, and Woodline Partners LP. “We are pleased by the support from this high-quality...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.